Citations

Clear

3314 citation(s) found for "Do, Alexander".

Models and Studies of Aging: Executive Summary of a Report from the U13 Conference Series
Hurria, Arti , Carpenter, Christopher R. , McFarland, Frances, Lundebjerg, Nancy E., Cabo, Rafael de , Ferrucci, Luigi , Studenski, Stephanie A. , Barzilai, Nir , Kitzman, Dalane W. , Kuchel, George A. , Musi, Nicolas , Newman, John C., Rando, Thomas A. , Smith, Alexander K. , Kirkland, James L. , Yung, Raymond , Carpenter, Christopher R , Ferrucci, Luigi , de Cabo, Rafael , Kuchel, George A , Briggs, Josephine P. , Ix, Joachim H. , Newman, John C., Walston, Jeremy D

Mayo Clinic

Journal of the American Geriatrics Society | January 29, 2019 | Volume: 67 | Issue: 3 | Pages: 428-433

10.1111/jgs.15788 | PMID 30693953 Get It

The American Geriatrics Society convened a conference in Bethesda, Maryland, to explore models and studies of aging. This was the second of three conferences, supported by a U13 grant from the National Institute on Aging, to aid recipients of Grants for Early Medical/Surgical Specialists Transition to Aging Research (GEMSSTAR) in integrating geriatrics into their specialties. Recognizing that aging is the largest risk factor for multiple chronic diseases and age‐related loss of resilience, the conference organizers focused scientific sessions on how targeting age‐related mechanisms can delay, prevent, or reverse geriatric syndromes, age‐related chronic diseases, and loss of resilience. The rationale for studying models of aging as well as study designs, strategies, and challenges of studying human aging were reviewed. This article provides a summary of the full conference report, Models and Studies of Aging: Report from the U13 Conference Series, and summarizes key take‐home messages that were designed to support GEMSSTAR awardees in developing their research careers focused on aging research (see supplementary text for the full report). J Am Geriatr Soc 67:428–433, 2019.
The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report
Ebeling, Peter R. , Bauer, Douglas C. , Eastell, Richard , Fink, Howard A , Guañabens, Núria , Kado, Deborah M. , Kallmes, David F. , Katzman, Wendy B. , Rodríguez, Alexander J. , Wermers, Robert A. , Wilson, H Alexander, Bouxsein, Mary , Kallmes, David, Wermers, Robert, Ebeling, Peter R , Bauer, Douglas C , Fink, Howard A , Åkesson, Kristina , Buchbinder, Rachelle , Giangregorio, Lora

Mayo Clinic

Journal of Bone and Mineral Research | January 24, 2019 | Volume: 34 | Issue: 1 | Pages: 3-21

10.1002/jbmr.3653 | PMID 30677181 Get It

ABSTRACT Vertebral augmentation is among the current standards of care to reduce pain in patients with vertebral fractures (VF), yet a lack of consensus regarding efficacy and safety of percutaneous vertebroplasty and kyphoplasty raises questions on what basis clinicians should choose one therapy over another. Given the lack of consensus in the field, the American Society for Bone and Mineral Research (ASBMR) leadership charged this Task Force to address key questions on the efficacy and safety of vertebral augmentation and other nonpharmacological approaches for the treatment of pain after VF. This report details the findings and recommendations of this Task Force. For patients with acutely painful VF, percutaneous vertebroplasty provides no demonstrable clinically significant benefit over placebo. Results did not differ according to duration of pain. There is also insufficient evidence to support kyphoplasty over nonsurgical management, percutaneous vertebroplasty, vertebral body stenting, or KIVA®. There is limited evidence to determine the risk of incident VF or serious adverse effects (AE) related to either percutaneous vertebroplasty or kyphoplasty. No recommendation can be made about harms, but they cannot be excluded. For patients with painful VF, it is unclear whether spinal bracing improves physical function, disability, or quality of life. Exercise may improve mobility and may reduce pain and fear of falling but does not reduce falls or fractures in individuals with VF. General and intervention-specific research recommendations stress the need to reduce study bias and address methodological flaws in study design and data collection. This includes the need for larger sample sizes, inclusion of a placebo control, more data on serious AE, and more research on nonpharmacologic interventions. Routine use of vertebral augmentation is not supported by current evidence. When it is offered, patients should be fully informed about the evidence. Anti-osteoporotic medications reduce the risk of subsequent vertebral fractures by 40–70%. © 2018 American Society for Bone and Mineral Research.
Haemodynamic Profiles in Adult Fontan Patients: Associated Haemodynamics and Prognosis
Miranda, William R. , Borlaug, Barry A. , Hagler, Donald J. , Connolly, Heidi M. , Egbe, Alexander C. , Borlaug, Barry A

Mayo Clinic

European Journal of Heart Failure | January 24, 2019 | Volume: 21 | Issue: 6 | Pages: 803-809

10.1002/ejhf.1365 | PMID 30672076 Get It

Abstract Aims The Fontan operation is associated with significant long-term morbidity and mortality, posing challenges in management. No haemodynamic classification has been established to aid management and prognostication of patients with Fontan palliation. Our aim was to assess haemodynamic profiles for Fontan patients and evaluate their relationships to prognosis. Methods and results Eighty-four adult Fontan patients without obstruction or significant valve disease undergoing cardiac catheterization for Fontan-related co-morbidities were divided into four different haemodynamic profiles based on normal/high Fontan pressures (FP) (< 15 or ≥ 15 mmHg) and low/normal cardiac index (CI) (< 2.5 or ≥ 2.5 L/min/m2). Fourteen patients had low CI/high FP (17%), 24 low CI/normal FP (29%), 20 normal CI/high FP (24%), and 26 normal CI/normal FP (31%). Demographic and clinical data were similar among groups except for a trend towards a higher prevalence of cirrhosis in the normal CI/high FP (50%) group. Systemic vascular afterload, assessed by systemic vascular resistance and effective arterial elastance, was higher in patients with low CI/high FP and low CI/normal FP as compared to normal CI profiles. Pulmonary vascular resistance indices were higher in patients with low CI/high FP than all other profiles. The normal CI/high FP haemodynamic profile was an independent predictor of mortality (hazard ratio 4.1, 95% confidence interval 1.2–11.5). Heterotaxy and protein-losing enteropathy were also predictors of mortality on the multivariate model. Conclusion The proposed haemodynamic classification provides prognostic information in adults post-Fontan with patients in the normal CI/high FP profile having worse survival. Whether this classification can guide management in these patients deserves further investigation.
Reply to Lutz-Bonengel et al.: Biparental mtDNA transmission is unlikely to be the result of nuclear mitochondrial DNA segments
Luo, Shiyu , Valencia, C. Alexander , Lee, Ni‐Chung , Slone, Jesse , Gui, Baoheng , Wang, Xinjian , Dell, Sarah, Brown, Jenice, Chen, Stella Maris, Hwu, Wuh‐Liang , Fan, Pi‐Chuan , Wong, Lee‐Jun C. , Huang, Taosheng , Li, Zhuo , Zhang, Jinglan , Li, Zhuo , Chien, Yin-Hsiu , Atwal, Paldeep S

Mayo Clinic

Proceedings of the National Academy of Sciences | January 23, 2019 | Volume: 116 | Issue: 6 | Pages: 1823-1824

10.1073/pnas.1821357116 | PMID 30674682 Get It

Acute Unilateral Vision Loss Due to Optic Neuropathy in a Patient with Systemic Lupus Erythematosus
Heckman, Alexander , Alsaad, Ali A. , Stewart, Michael W., Heckman, Alexander J, Maniaci, Michael J.

Mayo Clinic

American Journal of Case Reports | January 23, 2019 | Volume: 20 | Issue: No issue available | Pages: 97-100

10.12659/ajcr.912875 | PMID 30670677 Get It

Laparoscopic access to the liver and application of laparoscopic microwave ablation in 2 dogs with liver neoplasia
Oramas, Alberto, Case, J. Brad , Toskich, Beau , Fox‐Alvarez, W. Alexander, Boston, Sarah E., Giglio, Robson F., Dark, Michael J. , Toskich, Beau B. , Giglio, Robson F.

Mayo Clinic

Veterinary Surgery | January 22, 2019 | Volume: 48 | Issue: S1 | Pages: No page available

10.1111/vsu.13153 | PMID 30666685 Get It

AbstractObjectiveTo determine laparoscopic accessibility of liver lobes and access to the hilus and describe laparoscopic microwave ablation (LMWA) in 2 dogs with hepatic neoplasia.Study designExperimental/descriptive case series.Sample populationSix canine cadavers and 2 clinical dogs.MethodsCadavers in dorsal recumbency underwent laparoscopic assessment of the liver. A 17 gauge MWA probe was inserted to create an ablation zone at the most proximal aspect of the hilus. The distance from the center of each ablation zone to the most proximal aspect of the corresponding hilus was determined. Two dogs with hepatic neoplasia underwent LMWA.ResultsAll lobes of the canine liver were accessible via laparoscopy. The median (interquartile range) distances from the ablation zones to the hilus for the caudate process, left lateral, left middle, quadrate, right lateral, and right middle lobes were 2.2 (1.2–2.6), 2.1 (1–4.4), 1.5 (1.4–3.7), 2, 1, 2.5 (1–4.1) cm, respectively. Histopathologic diagnoses treated by LMWA included metastatic hemangiosarcoma and primary hepatocellular carcinoma. Laparoscopic microwave ablation was technically feasible, and no complications from the procedure resulted.ConclusionLaparoscopic access to the hilus of each liver lobe is possible via a ventrodorsal approach provided reverse Trendelenburg and lateral rotation is used, especially for the right lateral lobe. Laparoscopic microwave ablation is feasible in some dogs with hepatic neoplasia. The indications for and efficacy of LMWA for hepatic neoplasia in dogs requires additional investigation.Clinical significanceLaparoscopic access to all liver lobes and MWA of some neoplastic lesions is feasible in a canine pilot study.
Interactive reflective writing-enhanced reflection and professional identity formation in medical education – in reply to (1) Hichem Bouayed, Samiullah Dost, and Tanzeel Hussian and (2) Alexander Morgan, James Moore and Alexander Duff
Wald, Hedy S. , Anthony, David, White, Jordan , Reis, Shmuel , Esquibel, Angela Y., Esquibel, Angela

Mayo Clinic

Medical Teacher | January 20, 2019 | Volume: 41 | Issue: 2 | Pages: 236-237

10.1080/0142159x.2018.1543861 | PMID 30663478 Get It

The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction
Reddy, Yogesh N.V. , Obokata, Masaru , Koepp, Katlyn E. , Egbe, Alexander C. , Wiley, Brandon M. , Borlaug, Barry A. , Wiley, Brandon, Nishimura, Rick , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

Circulation Research | January 17, 2019 | Volume: 124 | Issue: 2 | Pages: 306-314

10.1161/circresaha.118.313832 | PMID 30582447 Get It

Rationale: Pulmonary vascular resistance fails to decrease appropriately during exercise in patients with heart failure with preserved ejection fraction (HFpEF). Interventions that enhance pulmonary vasodilation might be beneficial in this cohort but could also worsen left atrial hypertension, exacerbating lung congestion. Intravenous β-agonists reduce pulmonary vascular resistance but are not suitable for chronic use. Objective: We hypothesized that the inhaled β-adrenergic agonist albuterol would improve pulmonary vasodilation during exercise in patients with HFpEF, without increasing left heart filling pressures. Methods and Results: We performed a randomized, double-blind, placebo-controlled trial testing the effects of inhaled albuterol on resting and exercise hemodynamics in subjects with HFpEF using high-fidelity micromanometer catheters and expired gas analysis. The primary end point was pulmonary vascular resistance during exercise. Subjects with HFpEF (n=30) underwent resting and exercise hemodynamic assessment and were then randomized 1:1 to inhaled, nebulized albuterol or placebo. Rest and exercise hemodynamic testing was then repeated. Albuterol improved the primary end point of exercise pulmonary vascular resistance as compared with placebo (−0.6±0.5 versus +0.1±0.7 WU; P =0.003). Albuterol enhanced cardiac output reserve and right ventricular pulmonary artery coupling, reduced right atrial and pulmonary artery pressures, improved pulmonary artery compliance, and enhanced left ventricular transmural distending pressure (all P <0.01), with no increase in pulmonary capillary hydrostatic pressures. Conclusions: Albuterol improves pulmonary vascular reserve in patients with HFpEF without worsening left heart congestion. Further study is warranted to evaluate the chronic efficacy of β-agonists in HFpEF and other forms of pulmonary hypertension. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02885636.
Risk of Parkinson's disease dementia related to level I MDS PD‐MCI
Hoogland, Jeroen , Boel, Judith A., Bie, Rob M.A. de , Schmand, Ben , Geskus, Ronald B. , Dalrymple‐Alford, John C. , Adler, Charles H. , Junqué, Carme , Pedersen, Kenn Freddy , Mollenhauer, Brit , Goldman, Jennifer G. , Tröster, Alexander I. , Burn, David J. , Geurtsen, Gert J. , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Adler, C H , Goldman, Jennifer G , Dalrymple-Alford, John C , de Bie, Rob M A , Geurtsen, Gert J , Junque, Carme , Marras, Connie , Weintraub, Daniel , Litvan, Irene , Disease”, on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson

Mayo Clinic

Movement Disorders | January 17, 2019 | Volume: 34 | Issue: 3 | Pages: 430-435

10.1002/mds.27617 | PMID 30653248 Get It

AbstractBackgroundThe International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria.MethodsWe analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow‐up for conversion to Parkinson's disease dementia. Survival analysis evaluated their contribution to the hazard of Parkinson's disease dementia.ResultsLevel I mild cognitive impairment in PD, increasing age, male sex, and severity of PD motor signs independently increased the hazard of Parkinson's disease dementia. Level I and level II mild cognitive impairment in PD classification had similar discriminative ability with respect to the time to Parkinson's disease dementia.ConclusionsLevel I mild cognitive impairment in PD classification independently contributes to the hazard of Parkinson's disease dementia. This finding supports the prognostic validity of the abbreviated mild cognitive impairment in PD criteria. © 2019 International Parkinson and Movement Disorder Society
Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and K
Fillingham, Yale A. , Ramkumar, Dipak B. , Jevsevar, David S. , Yates, Adolph J. , Bini, Stefano A. , Memtsoudis, Stavros G. , Sayeed, Siraj A., Sah, Alexander P. , Valle, Craig J. Della , Clarke, Henry D. , Johnson, Rebecca L. , Schemitsch, Emil H.

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 14, 2019 | Volume: 44 | Issue: 1 | Pages: 7-11

10.1136/rapm-2018-000024 | PMID 30640647 Get It